跳至主要内容
临床试验/NCT06063005
NCT06063005招募中不适用

Clinical Study of Translocated Internal Limiting Membrane Flap Reposition for the Treatment of Idiopathic Macular Hole

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine1 个研究点 分布在 1 个国家目标入组 76 人开始时间: 2022年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
76
试验地点
1
主要终点
Best Corrected Visual Acuity

研究概览

简要总结

The main objective of this study is to evaluate the therapeutic effectiveness of the internal limiting membrane (ILM) peeling and translocation surgery compared to the conventional surgical approach for treating large idiopathic macular hole (IMH) through a well-designed prospective randomized controlled clinical trial. This study aims to compare the new surgical approach to the conventional approach in terms of improving visual function, promoting macular retinal anatomical healing, and enhancing patients' quality of life. By conducting this prospective clinical trial, establishing a database, and generating clinical reports and evidence-based medicine on the therapeutic efficacy of the ILM peeling and translocation surgery for large IMH.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
55 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participants who can understand the purpose of this clinical trial, volunteer to participate, sign an informed consent form, and can complete the postoperative follow-up on time.
  • Participants diagnosed with idiopathic macular hole (IMH).
  • Based on OCT scans, the minimum horizontal diameter of the macular hole is >500 and <900 µm.
  • Participants with an axial length <26.0mm and a myopic degree lower than 6D.
  • For participants with bilateral macular holes, the eye with a larger hole diameter will be included.

排除标准

  • Patients with the following retinal disorders: age-related macular degeneration, epi-macular membrane neovascularization, non-macular retinal tears, lesions of the retinal pigment epithelium and choroid, inherited or degenerative retinal diseases, optic neuropathies, retinal vascular diseases; patients with large macular holes accompanied by retinal detachment;
  • Patients with high myopia (axial length ≥ 26.0mm and myopia exceeding 6D);
  • Patients with a history of ocular trauma or retinal laser treatment;
  • Patients with glaucoma, ocular infections, inflammations, tumors, corneal diseases, or amblyopia;
  • Patients with contraindications to vitrectomy;
  • Patients with severe or unstable systemic diseases;
  • Patients with a fasting blood glucose level ≥ 9mmol/L before surgery;
  • Patients who participated in other clinical trials involving drugs or medical devices within 30 days prior to screening;
  • Patients with a history of intraocular surgery within 3 months prior to screening;
  • Patients with reduced visual function or vision in the contralateral eye as determined by the investigator;
  • Patients who are not considered suitable for enrollment by the investigator for other reasons.

结局指标

主要结局

Best Corrected Visual Acuity

时间窗: 1 week, 1 month, 3 months, 1 years, 2 years after the operation

The best corrected visual acuity indicates the best visual acuity with proper refractive correction.

次要结局

  • Closure rate(1 week, 1 month, 3 months, 1 years, 2 years after the operation)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Peiquan Zhao

Professor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

研究点 (1)

Loading locations...

相似试验